SA
$2.36
+0.06
(+2.61%)
As of Oct 21, 2026, 1:28 AM EDT
Price history
Sana Biotechnology Inc (SANA) is trading up at $2.36 (+2.61%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: February 4, 2021 · $25.00 offering · NASDAQ · View IPO details →
Sana Biotechnology Inc net income history (FY2019–FY2025)
Net income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$141.2M | −$286.1M | −$356.9M | −$272.6M | −$293.1M | −$272.7M | −$250.3M |
| Net income | −$130.8M | −$285.3M | −$355.9M | −$269.5M | −$283.3M | −$266.8M | −$244.2M |
| EPS (diluted) | −$26.68 | −$21.92 | −$2.14 | −$1.43 | −$1.46 | −$1.16 | −$0.96 |
| Balance sheet | |||||||
| Cash and equivalents | $81.8M | $124.8M | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M |
| Total assets | — | $730.3M | $1.13B | $822.7M | $565.3M | $501.0M | $416.9M |
| Total liabilities | — | $298.6M | $400.9M | $323.4M | $277.8M | $250.5M | $256.0M |
| Shareholders' equity | −$142.5M | −$421.2M | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M |
| Cash flow | |||||||
| Operating cash flow | −$85.5M | −$138.0M | −$251.1M | −$290.1M | −$253.6M | −$223.2M | −$143.8M |
| Capital expenditure | $26.1M | $23.9M | $29.9M | $20.9M | $20.0M | $33.4M | $938.0K |
| Free cash flow | −$111.6M | −$161.9M | −$280.9M | −$310.9M | −$273.6M | −$256.6M | −$144.8M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$61.8M | −$50.9M | −$50.6M | −$95.0M | −$43.5M | −$61.2M | −$48.6M | −$65.4M |
| Net income | −$59.9M | −$49.1M | −$49.4M | −$93.8M | −$42.2M | −$58.8M | −$47.2M | −$63.6M |
| EPS (diluted) | −$0.25 | −$0.21 | −$0.21 | −$0.39 | −$0.16 | −$0.20 | −$0.17 | −$0.22 |
| Balance sheet | ||||||||
| Cash and equivalents | $127.0M | $127.6M | $96.1M | $71.3M | $103.4M | $71.9M | $83.8M | $57.1M |
| Total assets | $559.4M | $501.0M | $445.5M | $361.6M | $435.4M | $416.9M | $373.6M | $431.5M |
| Total liabilities | $266.9M | $250.5M | $236.4M | $239.1M | $240.1M | $256.0M | $254.4M | $277.0M |
| Shareholders' equity | $292.5M | $250.5M | $209.1M | $122.6M | $195.3M | $160.9M | $119.2M | $154.6M |
| Cash flow | ||||||||
| Operating cash flow | −$51.8M | −$47.2M | −$48.7M | −$33.1M | −$29.4M | −$32.6M | −$37.4M | −$32.8M |
| Capital expenditure | $4.09M | $436.0K | $136.0K | −$112.0K | $41.0K | $873.0K | $288.0K | $1.62M |
| Free cash flow | −$55.9M | −$47.6M | −$48.8M | −$33.0M | −$29.5M | −$33.5M | −$37.7M | −$34.4M |
From Sana Biotechnology Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Sana Biotechnology Inc
- Headquarters
- Seattle, Washington From SEC filings, Oct 2026
Recent News (3)
-
Workday integrates Sana AI across multiple platforms
Workday integrates Sana AI across multiple platforms
-
Workday launches AI assistant Sana as new employee interface
Workday launches AI assistant Sana as new employee interface
-
Sana Biotechnology at Morgan Stanley conference: diabetes push leads
Sana Biotechnology at Morgan Stanley conference: diabetes push leads
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International